A study has shed new light on the mechanisms behind idiopathic inflammatory myopathies (myositis), a group of systemic ...

in the ongoing Phase 2/3 ALKIVIA study in adults with idiopathic inflammatory myopathies (IIM or myositis), following analysis of topline data from the Phase 2 portion of the study. ALKIVIA will ...

A scoping review finds close pathophysiological links between idiopathic inflammatory myopathies and autoimmune gluten-related disorders.

The investigators suggest that IL-6 might be the culprit and could, therefore, be a candidate for future studies of myositis therapy. Therapeutic options for patients with idiopathic inflammatory ...

Idiopathic inflammatory myopathies (myositis) are a rare group of autoimmune diseases that can be muscle specific or affect multiple organs including the skin, joints, lungs, gastrointestinal ...

Phase 2 data establish proof-of-concept of efgartigimod SC in myositisEnrollment to continue in Phase 3 across all three subtypes (IMNM, ASyS, DM) under evaluation in ALKIVIAPotential for ...

ALKIVIA Study Design The ALKIVIA study is a randomized, double-blind, placebo-controlled, multicenter, operationally seamless Phase 2/3 study of efgartigimod SC for the treatment of idiopathic ...

The ALKIVIA study is a randomized, double-blind, placebo-controlled, multicenter, operationally seamless phase 2/3 study of efgartigimod SC for the treatment of idiopathic inflammatory myopathies (IIM ...

Ntrust-2, a multi-center clinical trial, will evaluate NKX019 across three parallel cohorts, including patients with systemic sclerosis (SSc, scleroderma), idiopathic inflammatory myopathy (IIM, ...